Are hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen (anti‑HBc) testing sufficient to assess hepatitis B reactivation risk and determine need for antiviral prophylaxis before initiating rituximab therapy?

HBsAg and Anti-HBc Testing Before Rituximab

No, HBsAg and anti-HBc testing alone is NOT sufficient—you must also obtain baseline HBV DNA levels before initiating rituximab therapy, and anti-HBs status provides critical risk stratification information that should guide your prophylaxis versus monitoring decision. 1, 2

Required Baseline Testing

The FDA label for rituximab explicitly mandates screening for both HBsAg AND anti-HBc before treatment initiation 2. However, current guidelines go further:

Complete Baseline Panel Should Include:

• HBsAg (hepatitis B surface antigen)
• Anti-HBc (total antibody to hepatitis B core antigen)
• HBV DNA (viral load)
• Anti-HBs (antibody to hepatitis B surface antigen) - for risk stratification 1

Why HBV DNA Matters

Baseline HBV DNA is essential because it predicts reactivation risk and guides monitoring intensity. Higher baseline HBV DNA (≥20 IU/mL) independently predicts both HBV reactivation (adjusted HR 10.9) and HBV-associated hepatitis (adjusted HR 14.8) 3. The 2025 AGA guideline explicitly recommends HBV DNA testing if HBsAg and/or anti-HBc is positive 1.

Why Anti-HBs Status Matters for Risk Stratification

While the 2025 AGA guideline notes that "using anti-HBs status to guide antiviral prophylaxis for all risk groups is not supported by the evidence" 1, this statement requires nuanced interpretation:

The Evidence Shows:

• Anti-HBs negative patients: 27.3% reactivation rate
• Anti-HBs 10-100 IU/mL: 13.8% reactivation rate
• Anti-HBs >100 IU/mL: 3.5% reactivation rate 4

However, anti-HBs positivity does NOT eliminate risk. Case reports document HBV reactivation occurring despite positive anti-HBs in rituximab-treated patients 5. The systematic review data confirms lower but still substantial reactivation rates in anti-HBs positive patients (7.1% in hematologic diseases, 2.5% in non-hematologic) compared to anti-HBs negative patients (21.8% and 10.7% respectively) 6.

Combined Anti-HBc and Anti-HBs Risk Stratification:

Patients with high anti-HBc (≥6.41 IU/mL) AND low anti-HBs (<56.48 mIU/mL) have a hazard ratio of 17.29 for HBV reactivation 7. This combination identifies the highest-risk subset.

Management Algorithm for Rituximab Patients

If HBsAg Positive (Chronic HBV):

• Start antiviral prophylaxis immediately before rituximab
• Continue for at least 12 months after completing rituximab (B-cell depleting agent) 8, 1
• Use high-barrier-to-resistance antivirals (entecavir or tenofovir)
• Monitor HBV DNA every 6 months during therapy 8

If HBsAg Negative but Anti-HBc Positive (Resolved HBV):

Rituximab is HIGH RISK for reactivation (>10% risk) 1

Strongly recommend antiviral prophylaxis over monitoring 1:

• Start before rituximab initiation
• Continue for at least 12 months after completing rituximab 8, 1
• Reactivation rates in this population range from 50-64% without prophylaxis 3

Alternative monitoring approach (only if patient refuses prophylaxis AND can guarantee adherence):

• HBsAg and HBV DNA testing every 3 months during treatment
• Continue monitoring up to 12 months after last rituximab dose (delayed reactivation can occur years later) 8
• Start immediate antiviral therapy if HBsAg becomes positive OR HBV DNA ≥1,000 IU/mL 8

Critical Timing Issue:

Mean time to reactivation is 18.1 months after starting rituximab-based therapy 9, and reactivation risk continues to increase even 2 years after rituximab 3. This extended risk period makes the monitoring-only approach challenging in real-world practice.

Common Pitfalls to Avoid

1. Don't rely on anti-HBs positivity as protection: Reactivation occurs despite positive anti-HBs 5

2. Don't skip HBV DNA at baseline: You need this for risk stratification and to establish a baseline for monitoring 1, 3

3. Don't stop monitoring too early: Continue for at least 12 months post-rituximab, as delayed reactivation is well-documented 8, 3

4. Don't use lamivudine as first-line: Use high-barrier-to-resistance agents (entecavir or tenofovir) to prevent resistance 1

5. Real-world screening remains inadequate: Only 10.5% of patients receive timely HBV screening before rituximab in population-based studies, and reactivation predominantly occurs in unscreened patients 10

Bottom Line on Your Question

HBsAg and anti-HBc are the minimum required screening tests per FDA labeling 2, but they are insufficient for optimal management. You must also obtain baseline HBV DNA for proper risk assessment 1, and anti-HBs levels provide valuable prognostic information even though they don't eliminate the need for prophylaxis in rituximab patients 4, 6, 7. Given rituximab's high reactivation risk (>10%), antiviral prophylaxis is strongly recommended over monitoring alone for all anti-HBc positive patients 1.